Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for blood diseases - Schedules the opening of the first clinical site for the phase 1 clinical trial of Hemo-Car-T, a treatment for relapsed or refractory acute myeloid leukemia in adults, formally called HG-CT-1, for the third week of November. The site will open following clearance from the Institutional Review Board and a site initiation visit.
Chief Executive Officer Vladislav Sandler says: ‘For patients who have few remaining treatment options left, HG-CT-1 offers a potentially life-saving solution. We are eager to initiate this trial and generate data that will be essential in advancing this therapy toward broader clinical use. This milestone underscores our commitment to innovation and our dedication to addressing the urgent needs of patients with severe blood cancers.’
Current stock price: 1.34 pence, up 1.2% in London on Wednesday morning
12-month change: down 36%
Copyright 2024 Alliance News Ltd. All Rights Reserved.
